Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year

Real-world data on guselkumab, especially at times >6 months, are limited.
We performed a longitudinal, retrospective analysis on 307 patients with moderate–severe chronic plaque psoriasis (Psoriasis Area Severity Index [PASI] >10) treated with guselkumab for up to 12 months.
PASI 75, PASI 90, and PASI 100 were assessed at baseline and at 4, 12, 20, 28, 36, 44, and 52 weeks.
At 12 weeks, PASI 75, PASI 90, and PASI 100 were achieved in 56.4%, 33.6%, and 24.1% of patients, respectively. At 52 weeks, PASI 75, PASI 90, and PASI 100 were achieved in 82.7%, 68.7%, and 51.1% of patients, respectively. Patients without comorbidities and those naïve to previous biological therapy had better responses. The mean Dermatology Life Quality Index score decreased from 14.0 at baseline to 3.1 at 12 weeks and 1.6 at 6 months, which was maintained at later times. Similar improvements were seen in pruritus visual analog scale.
Guselkumab maintains its efficacy for up to 12 months among responders in a real-world cohort of patients with moderate–severe plaque psoriasis, confirming data from prior real-world studies with smaller cohorts and shorter duration of follow-up.

目前关于古塞奇尤单抗 (guselkumab) 的真实世界数据较为有限，尤其是用药时长超过6个月的相关数据。
本研究对307例接受古塞奇尤单抗治疗、治疗时长长达12个月的中重度慢性斑块状银屑病患者[银屑病面积与严重程度指数 (Psoriasis Area Severity Index, PASI) >10]开展了纵向回顾性分析。
研究分别在基线及第4、12、20、28、36、44、52周时，对患者的PASI 75、PASI 90及PASI 100指标进行评估。
在第12周时，分别有56.4%、33.6%及24.1%的患者达到PASI 75、PASI 90及PASI 100标准；至第52周时，这一比例分别升至82.7%、68.7%及51.1%。无合并症患者及既往未接受过生物制剂治疗的患者，应答效果更佳。
患者的平均皮肤病生活质量指数 (Dermatology Life Quality Index) 评分从基线时的14.0降至第12周的3.1及6个月时的1.6，且该改善在后续随访中得以维持。瘙痒视觉模拟评分 (pruritus visual analog scale) 也呈现出类似的改善趋势。
古塞奇尤单抗在本项中重度斑块状银屑病患者的真实世界队列中，对应答者的疗效可维持长达12个月，这一结果验证了既往队列规模更小、随访时长更短的真实世界研究数据。